CD52 and B-cell non-Hodgkin lymphoma: Regardless of which technique is used, however, we feel it is most desirable to perform this evaluation on a specimen obtained as recently as possible prior to the intended trial enrollment date, as the long-term stability of CD52 expression in aggressive B-cell lymphomas has not been rigorously evaluated.